发病机制
受体
疾病
过氧化物酶体增殖物激活受体
肾脏疾病
生物信息学
肾
核受体
转录因子
糖尿病
下调和上调
医学
糖尿病肾病
生物
激素
过氧化物酶体
癌症研究
电池类型
病态的
过氧化物酶体增殖物
小RNA
2型糖尿病
内科学
内分泌学
细胞
免疫学
信号转导
抄写(语言学)
评论文章
机制(生物学)
基因
作者
Zhi Zheng,Yunkuo Li,Yujie Pan
标识
DOI:10.1038/s41420-026-03117-8
摘要
Diabetic kidney disease (DKD), a prevalent microvascular complication of diabetes, is a leading cause of chronic kidney disease and end-stage renal disease. Moreover, it plays a crucial role in the morbidity and mortality of diabetic patients. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptor superfamily, are key regulators of energy homeostasis, with three distinct subtypes identified: PPARα, PPARγ, and PPARβ/δ. They regulate gene transcription associated with energy metabolism, differentiation, inflammation, and cellular development. In recent years, the increasing incidence of DKD has intensified interest in elucidating the mechanisms and roles of PPARs in DKD. Unlike previous reviews-which focused primarily on individual PPAR subtypes or isolated pathological processes-this review adopts a unique "cell-type-specific perspective." It systematically elucidates the distinct roles of all three PPAR isotypes (α, γ, and β/δ) across key renal cell types (podocytes, mesangial cells, tubular cells) in DKD. We also explore the potential influence of PPAR genetic polymorphisms on DKD susceptibility. Beyond conventional review frameworks, we propose an innovative therapeutic strategy encompassing PPAR-based multi-target synergistic approaches and nanotechnology-driven cell-specific targeted therapy. This offers novel directions to overcome current therapeutic bottlenecks.
科研通智能强力驱动
Strongly Powered by AbleSci AI